https://www.pharmaradar360.com/article/how-drone-delivery-is-moving-closer-to-pharma-s-last-mile-c0ae477b30f1ac1cPharma Surgeen2026-08-05T15:07:33.000ZHow Drone Delivery Is Moving Closer to Pharma's Last Milehttps://www.pharmaradar360.com/article/medicine-supply-management-49792371bdddb531Pharma Surgeen2026-08-05T14:55:41.000ZMedicine supply managementhttps://www.pharmaradar360.com/article/ensuring-the-efficient-supply-and-distribution-of-medicines-to-patients-ad6631405329da7bPharma Surgeen2026-08-05T14:50:37.000ZEnsuring the efficient supply and distribution of medicines to patientshttps://www.pharmaradar360.com/article/long-term-real-world-safety-and-effectiveness-of-arimoclomol-in-individuals-with-137c3fc85c443747Pharma Surgeen2026-08-05T14:37:42.000ZLong-term real-world safety and effectiveness of arimoclomol in individuals with NPC: Outcomes from the US early access program over a 4-year periodhttps://www.pharmaradar360.com/article/collegium-pharmaceutical-earnings-ahead-after-adhd-acquisition-by-investing-com-7563c8042079448ePharma Surgeen2026-08-05T14:25:44.000ZCollegium Pharmaceutical earnings ahead after ADHD acquisition By Investing.comhttps://www.pharmaradar360.com/article/what-kenco-s-ai-rollout-signals-for-3pl-6ae1a4363d17b4c0Pharma Surgeen2026-08-05T14:21:55.000ZWhat Kenco's AI Rollout Signals for 3PLhttps://www.pharmaradar360.com/article/building-a-more-resilient-healthcare-future-insights-from-aspen-s-dr-stavros-nic-c504d93cd0680379Pharma Surgeen2026-08-05T14:17:04.000ZBuilding a More Resilient Healthcare Future: Insights from Aspen’s Dr Stavros Nicolaouhttps://www.pharmaradar360.com/article/america-s-next-biotech-challenge-7a519961de832d68Pharma Surgeen2026-08-05T14:06:59.000ZAmerica’s Next Biotech Challengehttps://www.pharmaradar360.com/article/cspc-pharmaceutical-astrazeneca-form-joint-venture-for-biologics-manufacturing-i-b4881cb4abb4ee03Pharma Surgeen2026-08-05T14:02:36.000ZCSPC Pharmaceutical & AstraZeneca Form Joint Venture for Biologics Manufacturing in Chinahttps://www.pharmaradar360.com/article/investors-brace-for-vir-biotech-earnings-amid-turnaround-bid-by-investing-com-472a9b471e741d0ePharma Surgeen2026-08-05T13:56:48.000ZInvestors brace for Vir Biotech earnings amid turnaround bid By Investing.comhttps://www.pharmaradar360.com/article/novo-nordisk-stock-shock-has-investors-rethinking-obesity-drug-exposure-4f84f83916f6db31Pharma Surgeen2026-08-05T13:55:27.000ZNovo Nordisk Stock Shock Has Investors Rethinking Obesity Drug Exposurehttps://www.pharmaradar360.com/article/digital-inclusion-action-plan-one-year-on-1d3fd03658d0d477Pharma Surgeen2026-08-05T13:45:47.000ZDigital Inclusion Action Plan: One Year Onhttps://www.pharmaradar360.com/article/4dmt-reports-new-phase-2b-gene-therapy-data-for-wet-amd-6a0c45854be523b9Pharma Surgeen2026-08-05T13:39:20.000Z4DMT reports new phase 2b gene therapy data for wet AMDhttps://www.pharmaradar360.com/article/medera-partners-with-iqvia-to-accelerate-cardiac-gene-therapies-and-human-based-864a3f11c3144c06Pharma Surgeen2026-08-05T13:34:53.000ZMedera Partners with IQVIA to Accelerate Cardiac Gene Therapies and Human-Based Drug Discovery Platformshttps://www.pharmaradar360.com/article/moderna-launches-early-trial-of-ebola-mrna-vaccine-d45ac1e3f0eab751Pharma Surgeen2026-08-05T13:34:25.000ZModerna launches early trial of Ebola mRNA vaccinehttps://www.pharmaradar360.com/article/novartis-enrolled-first-participant-in-phase-3-preserve-clinical-trial-for-exper-d5f8cd2e0c0c6485Pharma Surgeen2026-08-05T13:00:45.000ZNovartis Enrolled First Participant in Phase 3 PRESERVE Clinical Trial for Experimental PSP-RS Treatmenthttps://www.pharmaradar360.com/article/north-carolina-pharmaceutical-company-laying-off-47-in-hoover-leaving-birmingham-3e3296c45085ecd6Pharma Surgeen2026-08-05T12:45:00.000ZNorth Carolina pharmaceutical company laying off 47 in Hoover, leaving Birmingham areahttps://www.pharmaradar360.com/article/fda-approves-long-lasting-otc-pain-reliever-combining-acetaminophen-and-naproxen-b705877d8a45bc85Pharma Surgeen2026-08-05T12:43:01.000ZFDA approves long-lasting OTC pain reliever combining acetaminophen and naproxenhttps://www.pharmaradar360.com/article/new-nsf-initiative-drives-ai-enabled-scientific-discovery-172e309b199542cfPharma Surgeen2026-08-05T12:38:00.000ZNew NSF initiative drives AI-enabled scientific discoveryhttps://www.pharmaradar360.com/article/missed-ai-memory-bull-run-biotech-may-be-the-next-breakout-trade-but-retail-sent-671bce17695a553aPharma Surgeen2026-08-05T12:32:17.000ZMissed AI, Memory Bull Run? Biotech May Be The Next Breakout Trade — But Retail Sentiment Has Never Been Lowerhttps://www.pharmaradar360.com/article/alteogen-announces-exclusive-license-agreement-with-a-global-pharmaceutical-comp-767e313e97ed282dPharma Surgeen2026-08-05T12:30:49.000ZAlteogen Announces Exclusive License Agreement with a Global Pharmaceutical Company for the Development and Commercialization of a Hybrozyme™-Enabled Subcutaneous Biologic Producthttps://www.pharmaradar360.com/article/adneuris-therapeutics-grants-exclusive-license-to-maruishi-pharmaceutical-to-adv-9adfeb9c1c198156Pharma Surgeen2026-08-05T12:30:00.000ZAdneuris Therapeutics Grants Exclusive License to Maruishi Pharmaceutical to Advance Cebranopadol in Japan and South Koreahttps://www.pharmaradar360.com/article/five-biospace-nextgen-companies-account-for-one-third-of-2026-biotech-ipos-e4719d9059366612Pharma Surgeen2026-08-05T12:18:30.000ZFive BioSpace NextGen Companies Account for One-Third of 2026 Biotech IPOshttps://www.pharmaradar360.com/article/research-innovators-finding-a-cure-introduces-students-to-pharmaceutical-careers-6fc9cf15d7d8d59aPharma Surgeen2026-08-05T12:02:35.000ZResearch Innovators Finding a Cure introduces students to pharmaceutical careershttps://www.pharmaradar360.com/article/filmarray-ngds-warrior-panel-24e67aca8615b8d0Pharma Surgeen2026-08-05T12:00:00.000ZFilmArray® NGDS Warrior Panelhttps://www.pharmaradar360.com/article/systimmune-announces-first-patient-dosed-in-global-phase-3-trial-of-bl-m14d1-in-61f74eb64819f62aPharma Surgeen2026-08-05T12:00:00.000ZSystImmune Announces First Patient Dosed in Global Phase 3 Trial of BL-M14D1 in First-Line Extensive-Stage Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/expedition-gets-another-115m-for-its-twist-on-china-newco-model-35b44d19760c8482Pharma Surgeen2026-08-05T12:00:00.000ZExpedition gets another $115M for its twist on China NewCo modelhttps://www.pharmaradar360.com/article/what-is-premium-content-on-pharmaceutical-technology-3346b038dd63c932Pharma Surgeen2026-08-05T11:54:14.000ZWhat is ‘Premium Content’ on Pharmaceutical Technology?https://www.pharmaradar360.com/article/son-of-lukashenka-s-alleged-partner-to-build-10m-pharmaceutical-plant-in-belarus-42d2c12e1b963462Pharma Surgeen2026-08-05T11:44:00.000ZSon of Lukashenka’s alleged partner to build $10M pharmaceutical plant in Belarushttps://www.pharmaradar360.com/article/kane-biotech-announces-engagement-of-dna-advisors-1f12fff0849db646Pharma Surgeen2026-08-05T11:38:19.000ZKane Biotech Announces Engagement of DNA Advisorshttps://www.pharmaradar360.com/article/charles-river-lifts-profit-forecast-on-improving-biotech-demand-c9fe8a74e8ea8d03Pharma Surgeen2026-08-05T11:34:59.000ZCharles River lifts profit forecast on improving biotech demandhttps://www.pharmaradar360.com/article/european-pharmacopoeia-opens-revised-monograph-macrogols-1444-for-consultation-57f3b969f8d63478Pharma Surgeen2026-08-05T11:29:26.000ZEuropean Pharmacopoeia opens revised monograph Macrogols (1444) for consultationhttps://www.pharmaradar360.com/article/kane-biotech-announces-engagement-of-dna-advisors-a23eee2cc4cefae5Pharma Surgeen2026-08-05T11:25:00.000ZKane Biotech Announces Engagement of DNA Advisorshttps://www.pharmaradar360.com/article/kane-reviews-options-wound-care-activity-began-in-u-s-and-canada-02f9b163c46aaf67Pharma Surgeen2026-08-05T11:25:00.000ZKane reviews options; wound-care activity began in U.S. and Canadahttps://www.pharmaradar360.com/article/applied-biologics-receives-central-irb-approval-for-phase-3-bioxhealtm-clinical-b54821630f8b4e95Pharma Surgeen2026-08-05T11:21:00.000ZApplied Biologics Receives Central IRB Approval for Phase 3 BIOxHEAL™ Clinical Trialhttps://www.pharmaradar360.com/article/la-aemps-informa-del-posible-fallo-en-un-componente-electrico-interno-de-determi-deea90efa7cc20d6Pharma Surgeen2026-08-05T11:16:16.000ZLa AEMPS informa del posible fallo en un componente eléctrico interno de determinados ventiladores Astral 100 y Astral 150https://www.pharmaradar360.com/article/fur-real-biotech-startup-eliminates-major-dog-allergen-in-beagle-pups-using-cris-9e6f9ac5cf6633c2Pharma Surgeen2026-08-05T11:00:39.000ZFur Real: Biotech Startup Eliminates Major Dog Allergen in Beagle Pups Using CRISPRhttps://www.pharmaradar360.com/article/attovia-extends-biotech-ipo-streak-with-289m-listing-for-three-i-i-drugs-7b7fbc7139e99ac8Pharma Surgeen2026-08-05T11:00:00.000ZAttovia extends biotech IPO streak with $289M listing for three I&I drugshttps://www.pharmaradar360.com/article/attovia-s-ceo-aims-to-scratch-itch-opportunity-and-challenge-dupixent-with-289m-2d42d2c063a06174Pharma Surgeen2026-08-05T10:58:58.000ZAttovia's CEO aims to scratch itch opportunity and challenge Dupixent with $289M IPOhttps://www.pharmaradar360.com/article/lilly-reports-second-quarter-2026-financial-results-raises-full-year-guidance-an-e28fa132935883a2Pharma Surgeen2026-08-05T10:45:00.000ZLilly reports second-quarter 2026 financial results, raises full-year guidance, and highlights continued growth and pipeline progresshttps://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-q2-loss-narrows-as-revenue-rises-2026-revenue-guidance-6cfae01a9d19e198Pharma Surgeen2026-08-05T10:38:03.000ZUltragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmedhttps://www.pharmaradar360.com/article/why-is-my-baby-being-offered-an-rsv-immunisation-7a9d75715e3cc53cPharma Surgeen2026-08-05T10:04:03.000ZWhy is my baby being offered an RSV immunisation?https://www.pharmaradar360.com/article/rockville-based-supernus-to-become-2-2-billion-pharmaceutical-company-through-me-7b25f31e71fb163bPharma Surgeen2026-08-05T10:00:08.000ZRockville-Based Supernus to Become $2.2 Billion Pharmaceutical Company Through Mergerhttps://www.pharmaradar360.com/article/gcc-expands-pharmaceutical-manufacturing-as-market-surpasses-30-billion-b0816bda893f2ba1Pharma Surgeen2026-08-05T09:58:35.000ZGCC expands pharmaceutical manufacturing as market surpasses $30 billionhttps://www.pharmaradar360.com/article/teva-pharmaceutical-industries-ltd-teva-shares-purchased-by-royal-bank-of-canada-ed2bd672b94caea2Pharma Surgeen2026-08-05T09:54:02.000ZTeva Pharmaceutical Industries Ltd. $TEVA Shares Purchased by Royal Bank of Canadahttps://www.pharmaradar360.com/article/he-grew-up-near-boston-went-to-harvard-and-worked-at-mit-why-did-he-found-his-co-a5c0e4dda8298d9fPharma Surgeen2026-08-05T09:48:40.000ZHe grew up near Boston, went to Harvard, and worked at MIT. Why did he found his company in California?https://www.pharmaradar360.com/article/novo-nordisk-sues-eli-lilly-over-glp-1-advertising-expanding-scrutiny-of-drug-ma-cebc26e87e092246Pharma Surgeen2026-08-05T09:45:00.000ZNovo Nordisk sues Eli Lilly over GLP-1 advertising, expanding scrutiny of drug marketinghttps://www.pharmaradar360.com/article/zika-virus-sample-testing-advice-89184a09fce05a86Pharma Surgeen2026-08-05T09:38:55.000ZZika virus: sample testing advicehttps://www.pharmaradar360.com/article/this-company-should-be-in-massachusetts-bafcd7b9255cf680Pharma Surgeen2026-08-05T09:31:21.000ZThis company should be in Massachusettshttps://www.pharmaradar360.com/article/rovi-obtiene-la-medalla-gold-de-ecovadis-2026-y-mejora-su-puntuacion-global-hast-3e85a6406f058e6fPharma Surgeen2026-08-05T09:12:51.000ZROVI obtiene la medalla Gold de EcoVadis 2026 y mejora su puntuación global hasta los 83 puntoshttps://www.pharmaradar360.com/article/cryptosporidium-reference-unit-cru-e05d73b8212a95fcPharma Surgeen2026-08-05T09:07:05.000ZCryptosporidium Reference Unit (CRU)https://www.pharmaradar360.com/article/guidance-innovative-licensing-and-access-pathway-ilap-ec2fdf4140ef6775Pharma Surgeen2026-08-05T08:56:32.000ZGuidance: Innovative Licensing and Access Pathway (ILAP)https://www.pharmaradar360.com/article/takeda-pharmaceutical-seeks-india-s-backing-for-landmark-dengue-shot-43876e47bdef9e46Pharma Surgeen2026-08-05T08:53:11.000ZTakeda Pharmaceutical Seeks India's Backing for Landmark Dengue Shothttps://www.pharmaradar360.com/article/our-governance-e19412108cc777acPharma Surgeen2026-08-05T08:52:06.000ZOur governancehttps://www.pharmaradar360.com/article/pneumococcal-the-green-book-chapter-f14ee0573ebe09c4Pharma Surgeen2026-08-05T08:40:38.000ZPneumococcal: the green book chapterhttps://www.pharmaradar360.com/article/stronger-q2-results-guidance-hike-buybacks-might-change-the-case-for-investing-i-a99364df6d183fe7Pharma Surgeen2026-08-05T08:37:17.000ZStronger Q2 Results, Guidance Hike, Buybacks Might Change The Case For Investing In West (WST)https://www.pharmaradar360.com/article/cspc-pharmaceutical-and-astrazeneca-enter-jv-for-biologics-facility-in-china-68a5d3ab1d489d5cPharma Surgeen2026-08-05T08:32:47.000ZCSPC Pharmaceutical And AstraZeneca Enter JV For Biologics Facility In Chinahttps://www.pharmaradar360.com/article/mrsa-mssa-gram-negative-bacteraemia-and-cdi-monthly-data-2025-to-2026-46183ecdfec674ccPharma Surgeen2026-08-05T08:30:00.000ZMRSA, MSSA, Gram-negative bacteraemia and CDI: monthly data, 2025 to 2026https://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-data-to-june-2026-a79028947f82a41ePharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UK: data to June 2026https://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-background-and-methodology-8c464f884dfbd989Pharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UK: background and methodologyhttps://www.pharmaradar360.com/article/medicine-supply-disruption-statistics-uk-1809a1bb48d946faPharma Surgeen2026-08-05T08:30:00.000ZMedicine supply disruption statistics, UKhttps://www.pharmaradar360.com/article/c-suite-changes-help-biotech-narrow-focus-but-maintain-drive-to-treat-fatal-neon-e425a5fd6796574dPharma Surgeen2026-08-05T08:03:10.000ZC-Suite Changes Help Biotech Narrow Focus But Maintain Drive To Treat Fatal Neonatal Brain Injuryhttps://www.pharmaradar360.com/article/weekly-all-cause-mortality-surveillance-week-ending-2-august-2026-9727509b061a9ef9Pharma Surgeen2026-08-05T08:00:17.000ZWeekly all-cause mortality surveillance: week ending 2 August 2026https://www.pharmaradar360.com/article/maharashtra-govt-bans-analogue-paneer-for-one-year-cites-food-safety-norm-violat-721ba054adf0af79Pharma Surgeen2026-08-05T07:43:03.000ZMaharashtra Govt Bans Analogue Paneer For One Year, Cites Food Safety Norm Violationshttps://www.pharmaradar360.com/article/litmus-changes-the-biopsy-calculus-what-the-nature-medicine-data-means-for-your-56106ecf83a9d08aPharma Surgeen2026-08-05T07:37:44.000ZLITMUS Changes the Biopsy Calculus: What the Nature Medicine Data Means for Your MASLD Protocolhttps://www.pharmaradar360.com/article/first-aid-biotech-act-divides-industry-patients-63292efba5ba981ePharma Surgeen2026-08-05T07:35:41.000ZFIRST AID: Biotech Act divides industry, patientshttps://www.pharmaradar360.com/article/from-licensing-deals-to-patients-ligachem-and-abl-bio-shift-focus-to-clinical-pr-5c15b1d86e415071Pharma Surgeen2026-08-05T07:12:03.000ZFrom licensing deals to patients: LigaChem and ABL Bio shift focus to clinical proofhttps://www.pharmaradar360.com/article/fda-portal-flooded-with-rivalry-driven-plaints-496ecf376d12b03ePharma Surgeen2026-08-05T07:08:09.000ZFDA portal flooded with rivalry-driven plaintshttps://www.pharmaradar360.com/article/from-molecule-to-medicine-the-process-behind-patient-ready-treatments-fe203f072693fe55Pharma Surgeen2026-08-05T07:00:00.000ZFrom molecule to medicine: the process behind patient-ready treatmentshttps://www.pharmaradar360.com/article/chinese-biotech-giant-wuxi-apptech-sees-h1-earnings-grow-1-3-e5857427affb307aPharma Surgeen2026-08-05T06:58:31.000ZChinese biotech giant WuXi AppTech sees H1 earnings grow 1/3https://www.pharmaradar360.com/article/why-china-s-biotech-rise-is-harder-to-contain-than-ai-4b6ef08548a33243Pharma Surgeen2026-08-05T06:53:54.000ZWhy China’s biotech rise is harder to contain than AIhttps://www.pharmaradar360.com/article/shy-therapeutics-doses-first-patient-in-shy-onc6-phase-1-trial-for-solid-tumors-2e3d6b5cf649f967Pharma Surgeen2026-08-05T06:48:36.000ZSHY Therapeutics Doses First Patient in SHY-ONC6 Phase 1 Trial for Solid Tumorshttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-oxygenta-pharmaceutical-limited-bse-oxyge-04b1a5414726867bPharma Surgeen2026-08-05T06:41:44.000ZEnterprise value to revenue forward of Oxygenta Pharmaceutical Limited – BSE:OXYGENTAPHhttps://www.pharmaradar360.com/article/oric-launches-phase-3-trial-of-rinzimetostat-in-metastatic-prostate-cancer-d698ea9cb43392c6Pharma Surgeen2026-08-05T06:38:36.000ZORIC Launches Phase 3 Trial of Rinzimetostat in Metastatic Prostate Cancerhttps://www.pharmaradar360.com/article/q1-fy2026-financial-results-fa230a573f5915d5Pharma Surgeen2026-08-05T06:30:00.000ZQ1/FY2026 Financial resultshttps://www.pharmaradar360.com/article/lab-monkeys-for-26-000-show-china-s-biotech-quest-to-rival-us-23129f374f578896Pharma Surgeen2026-08-05T06:05:00.000ZLab Monkeys for $26,000 Show China’s Biotech Quest to Rival UShttps://www.pharmaradar360.com/article/la-aemps-informa-de-que-los-lotes-de-las-vacunas-veterinarias-monovalentes-frent-4e7733db4dc3f339Pharma Surgeen2026-08-05T06:00:41.000ZLa AEMPS informa de que los lotes de las vacunas veterinarias monovalentes frente a IBR, PIF y rabia requerirán de un certificado OBPR antes de su liberación y comercialización en Españahttps://www.pharmaradar360.com/article/asx-quarterly-health-wrap-regulatory-wins-clinical-progress-and-strategic-growth-b49063a198c2b227Pharma Surgeen2026-08-05T05:57:53.000ZASX Quarterly Health Wrap: Regulatory wins, clinical progress and strategic growthhttps://www.pharmaradar360.com/article/sterling-biotech-e2f02e10ec355aacPharma Surgeen2026-08-05T05:56:40.000ZSterling Biotechhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-cisen-pharmaceutical-ltd-class-a-sse-6033-658b8dc2e2a223e6Pharma Surgeen2026-08-05T05:04:44.000ZEnterprise value to revenue forward of Cisen Pharmaceutical Ltd. Class A – SSE:603367https://www.pharmaradar360.com/article/3d216ef31de7c8cdPharma Surgeen2026-08-05T05:03:12.000ZΑνάκληση της Άδειας Χονδρικής πώλησης φαρμάκων για Ανθρώπινη Χρήση στη φαρμακαποθήκη ΜΕΝΤΙΚΑΜΕΡΚ ΑΕhttps://www.pharmaradar360.com/article/sls-stock-kicks-off-week-in-green-ceo-flags-role-in-eu-biotech-policy-talks-that-85917f0651d26f85Pharma Surgeen2026-08-05T04:48:07.000ZSLS Stock Kicks Off Week In Green: CEO Flags Role In EU Biotech Policy Talks That Could Impact Drug Approvalshttps://www.pharmaradar360.com/article/cbd-gummies-safety-concerns-drug-interactions-2025-view-xxtwryucy-92683ddca5916e94Pharma Surgeen2026-08-05T04:31:08.000Zcbd gummies safety concerns drug interactions 2025 - View XxTWryucyhttps://www.pharmaradar360.com/article/4-potential-biotech-m-a-targets-plus-a-pretty-sure-bet-from-j-j-8a7357e0db65cbd0Pharma Surgeen2026-08-05T04:14:26.000Z4 potential biotech M&A targets, plus a pretty sure bet from J&Jhttps://www.pharmaradar360.com/article/novo-nordisk-shares-drop-after-drug-candidate-fails-in-trial-b758367c05ecb619Pharma Surgeen2026-08-05T04:00:50.000ZNovo Nordisk Shares Drop After Drug Candidate Fails in Trialhttps://www.pharmaradar360.com/article/3-biotech-stocks-with-massive-upside-to-buy-before-august-starts-c5467ef6dfd806f7Pharma Surgeen2026-08-05T03:53:36.000Z3 Biotech Stocks With Massive Upside to Buy Before August Startshttps://www.pharmaradar360.com/article/collegium-pharmaceutical-coll-reports-earnings-tomorrow-what-to-expect-a03c473e79b7bf4cPharma Surgeen2026-08-05T03:36:00.000ZCollegium Pharmaceutical (COLL) Reports Earnings Tomorrow: What To Expecthttps://www.pharmaradar360.com/article/biomarin-pharmaceutical-bmrn-to-report-earnings-tomorrow-here-is-what-to-expect-98bd29becad5381fPharma Surgeen2026-08-05T03:34:18.000ZBioMarin Pharmaceutical (BMRN) To Report Earnings Tomorrow: Here Is What To Expecthttps://www.pharmaradar360.com/article/shinsa-list-of-approved-regenerative-medical-products-april-2015-to-may-2026-13a81e82d9986c86Pharma Surgeen2026-08-05T03:00:00.000Z[SHINSA]List of Approved Regenerative Medical Products: April 2015 to May 2026https://www.pharmaradar360.com/article/onshoring-is-here-the-hiring-wave-is-still-a-decade-out-5296ecb39c08ed29Pharma Surgeen2026-08-05T02:52:14.000ZOnshoring Is Here. The Hiring Wave Is Still a Decade Outhttps://www.pharmaradar360.com/article/rohto-pharmaceutical-co-revenue-breakdown-otc-rphcf-1aa246098af6d55aPharma Surgeen2026-08-05T02:51:57.000ZRohto Pharmaceutical Co. Revenue Breakdown – OTC:RPHCFhttps://www.pharmaradar360.com/article/phase-3-korean-trial-backs-carboplatin-in-early-triple-negative-breast-cancer-39ef1905c63d2636Pharma Surgeen2026-08-05T02:43:46.000ZPhase 3 Korean trial backs carboplatin in early triple-negative breast cancerhttps://www.pharmaradar360.com/article/is-cbd-gummies-fda-approved-view-h2rzie3s8-470a235d153320dbPharma Surgeen2026-08-05T02:22:48.000Zis cbd gummies fda approved - View H2rZIE3s8https://www.pharmaradar360.com/article/enterprise-value-to-ebit-forward-of-biotech-growth-trust-plc-lse-biog-57341996fdf8bde7Pharma Surgeen2026-08-05T02:12:08.000ZEnterprise value to EBIT forward of Biotech Growth Trust PLC – LSE:BIOGhttps://www.pharmaradar360.com/article/big-pharma-reshuffles-split-korea-biotech-as-assets-race-toward-trials-and-sales-d2e232d8e20f32e9Pharma Surgeen2026-08-05T02:10:00.000ZBig pharma reshuffles split Korea biotech as assets race toward trials and sales - CHOSUNBIZhttps://www.pharmaradar360.com/article/enterprise-value-to-ebitda-forward-of-ch-biotech-r-d-co-ltd-twse-6534-4a020f4d24657380Pharma Surgeen2026-08-05T02:07:42.000ZEnterprise value to EBITDA forward of CH Biotech R&D Co., Ltd. – TWSE:6534https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-q2-earnings-call-highlights-1df183332e9464caPharma Surgeen2026-08-05T02:03:00.000ZUltragenyx Pharmaceutical Q2 Earnings Call Highlightshttps://www.pharmaradar360.com/article/widened-access-to-diabetes-medicines-to-benefit-over-30-000-new-zealanders-8586aadb23c90779Pharma Surgeen2026-08-05T02:00:00.000ZWidened access to diabetes medicines to benefit over 30,000 New Zealandershttps://www.pharmaradar360.com/article/california-biotech-company-erectile-dysfunction-view-9xve7uzrx-403b6b29bdb1d649Pharma Surgeen2026-08-05T01:50:39.000ZCalifornia Biotech Company Erectile Dysfunction - View 9xVe7uZrXhttps://www.pharmaradar360.com/article/cbd-gummies-safety-who-should-avoid-interactions-view-lbc1j3ccr-656127e539d84134Pharma Surgeen2026-08-05T01:49:25.000ZCBD Gummies Safety: Who Should Avoid Interactions - View lbc1J3CCrhttps://www.pharmaradar360.com/article/taiwan-launches-nt-10b-fund-to-back-biotech-commercialization-2168afe35652086ePharma Surgeen2026-08-05T01:45:00.000ZTaiwan launches NT$10B fund to back biotech commercializationhttps://www.pharmaradar360.com/article/goldman-backed-biotech-attovia-raises-289-million-in-us-ipo-07b7164ef9075fd3Pharma Surgeen2026-08-05T01:44:01.000ZGoldman-Backed Biotech Attovia Raises $289 Million in US IPOhttps://www.pharmaradar360.com/article/who-is-eligible-to-get-eli-lilly-s-experimental-weight-loss-drug-before-approval-596b25472cdf0fe2Pharma Surgeen2026-08-05T01:30:00.000ZWho Is Eligible To Get Eli Lilly's Experimental Weight Loss Drug Before Approval? Criteria Explainedhttps://www.pharmaradar360.com/article/geno-pharmatech-showcases-comprehensive-pharmaceutical-facility-solutions-for-bi-fbe3f1c9450ddcb6Pharma Surgeen2026-08-05T01:05:00.000ZGENO Pharmatech Showcases Comprehensive Pharmaceutical Facility Solutions for Biotech Buyers Seeking GMP Cleanroom Construction and Turnkey Cleanroom EPC Expertisehttps://www.pharmaradar360.com/article/exilby-fda-fast-tracks-cannabis-derived-painkiller-disrupting-multi-billion-doll-5d5d3bb3171b1501Pharma Surgeen2026-08-05T00:38:32.000ZExilby: FDA Fast-Tracks Cannabis-Derived Painkiller Disrupting Multi-Billion-Dollar Opioid Industryhttps://www.pharmaradar360.com/article/cbd-gummies-safety-who-should-avoid-them-according-to-fda-stance-view-bzizhv2ya-5af4f39494df27c4Pharma Surgeen2026-08-05T00:28:21.000ZCBD Gummies Safety: Who Should Avoid Them According to FDA Stance - View bzizhV2yahttps://www.pharmaradar360.com/article/cbd-gummies-fda-regulation-safety-third-party-testing-view-h07c7bpku-91fe4e27718a2301Pharma Surgeen2026-08-05T00:20:59.000Zcbd gummies fda regulation safety third-party testing - View H07C7BpKuhttps://www.pharmaradar360.com/article/excipient-selection-strategies-to-mitigate-nitrosamine-risks-812ded3585d60c32Pharma Surgeen2026-08-05T00:19:10.000ZExcipient Selection Strategies to Mitigate Nitrosamine Riskshttps://www.pharmaradar360.com/article/eli-lilly-filed-form-8-k-6399e210c7d422cbPharma Surgeen2026-08-05T00:00:00.000ZEli Lilly filed Form 8-Khttps://www.pharmaradar360.com/article/amgen-filed-form-10-q-b55e3dbf47bbc6a9Pharma Surgeen2026-08-05T00:00:00.000ZAmgen filed Form 10-Qhttps://www.pharmaradar360.com/article/08-05-2026-press-release-ir-news-santen-joins-inaugural-global-summit-for-eye-he-9b6412eeab8ac791Pharma Surgeen2026-08-05T00:00:00.000Z08.05.2026 Press Release IR News Santen Joins Inaugural Global Summit for Eye Health as High-Impact Partnerhttps://www.pharmaradar360.com/article/natco-records-e2-82-b9816-9-crore-consolidated-revenue-and-e2-82-b9269-0-crore-o-200c0288770d345dPharma Surgeen2026-08-05T00:00:00.000Znatco records %e2%82%b9816 9 crore consolidated revenue and %e2%82%b9269 0 crore of profit after tax for q4 fy26 and %e2%82%b94375 9 crore of revenue %e2%82%b91418 5 crore profit after tax for fy26https://www.pharmaradar360.com/article/natco-records-e2-82-b9705-4-crore-consolidated-revenue-and-e2-82-b9151-3-crore-o-6ca56f300e0bf0f5Pharma Surgeen2026-08-05T00:00:00.000Znatco records %e2%82%b9705 4 crore consolidated revenue and %e2%82%b9151 3 crore of profit after tax for q3fy26https://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-olaparib-tablets-from-the-united-states-fo-b7d66150b69a2e43Pharma Surgeen2026-08-05T00:00:00.000Znatco receives tentative approval for olaparib tablets from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-tentative-approval-for-erdafitinib-tablets-generic-of-balversa-fr-a83d7e646c242805Pharma Surgeen2026-08-05T00:00:00.000Znatco receives tentative approval for erdafitinib tablets generic of balversa from the united states food and drug administration u s fdahttps://www.pharmaradar360.com/article/natco-receives-approval-from-central-drug-standard-control-organisation-cdsco-fo-4799708cbef44a99Pharma Surgeen2026-08-05T00:00:00.000Znatco receives approval from central drug standard control organisation cdsco for semaglutide in indiahttps://www.pharmaradar360.com/article/natco-pharma-limited-gets-approval-from-its-board-of-directors-for-increasing-it-ce7da44aad03f677Pharma Surgeen2026-08-05T00:00:00.000Znatco pharma limited gets approval from its board of directors for increasing its stake in adcock ingram holdings proprietary limited to 49https://www.pharmaradar360.com/article/natco-pharma-limited-completes-acquisition-of-additional-13-25-stake-in-adcock-i-a120934c71105609Pharma Surgeen2026-08-05T00:00:00.000Znatco pharma limited completes acquisition of additional 13 25 stake in adcock ingram holdings proprietary limitedhttps://www.pharmaradar360.com/article/natco-pharma-limited-api-unit-in-chennai-receives-establishment-inspection-repor-edbba0f6d5b05dfdPharma Surgeen2026-08-05T00:00:00.000Znatco pharma limited api unit in chennai receives establishment inspection report eir from u s fdahttps://www.pharmaradar360.com/article/natco-pharma-launches-semaglutide-generic-injection-multi-dose-vials-in-india-at-e72a497c6756ba1aPharma Surgeen2026-08-05T00:00:00.000Znatco pharma launches semaglutide generic injection multi dose vials in india at the most affordable price starting from mrp inr 1290https://www.pharmaradar360.com/article/natco-announces-launch-of-pomalidomide-capsules-generic-of-pomalyst-in-the-u-s-m-ac125cd024682c24Pharma Surgeen2026-08-05T00:00:00.000Znatco announces launch of pomalidomide capsules generic of pomalyst in the u s markethttps://www.pharmaradar360.com/article/natco-and-lupin-receive-approval-from-u-s-fda-for-eribulin-mesylate-injection-cbe6030c5ef55a0bPharma Surgeen2026-08-05T00:00:00.000Znatco and lupin receive approval from u s fda for eribulin mesylate injectionhttps://www.pharmaradar360.com/article/intimation-under-regulation-30-of-sebi-listing-obligations-and-disclosure-requir-9f4672667e17e0ebPharma Surgeen2026-08-05T00:00:00.000Zintimation under regulation 30 of sebi listing obligations and disclosure requirements regulations 2015 2https://www.pharmaradar360.com/article/disclosure-under-regulation-30-of-the-sebi-listing-obligations-and-disclosure-re-3b817678441a5e4aPharma Surgeen2026-08-05T00:00:00.000Zdisclosure under regulation 30 of the sebi listing obligations and disclosure requirements regulations 2015https://www.pharmaradar360.com/article/home-page-e5e4c966aad291cdPharma Surgeen2026-08-05T00:00:00.000ZHome pagehttps://www.pharmaradar360.com/article/micro-tracers-inc-response-to-objections-and-requests-for-a-public-hearing-c305e48be3e49778Pharma Surgeen2026-08-05T00:00:00.000ZMicro-Tracers, Inc.; Response to Objections and Requests for a Public Hearinghttps://www.pharmaradar360.com/article/center-for-scientific-review-notice-of-closed-meetings-11aa746e7211d87ePharma Surgeen2026-08-05T00:00:00.000ZCenter for Scientific Review; Notice of Closed Meetingshttps://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-grant-to-fund-fundacion-mexico-estados-unidos-a7e6c13247cf272bPharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single Source Grant To Fund Fundacion Mexico-Estados Unidos Para La Ciencia, A.C.https://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-grant-to-fund-fondacioni-secid-balkan-region-485078f5e8f41263Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single-Source Grant To Fund Fondacioni SECID, Balkan Regionhttps://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-grant-to-fund-hjf-medical-research-internatio-f7e856fa0ea599ccPharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single-Source Grant To Fund HJF Medical Research International, Inc., Kenyahttps://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-cooperative-agreement-to-fund-task-force-for-98e148bd43ec527cPharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single Source Cooperative Agreement To Fund Task Force for Global Health, Inc.https://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-grant-to-fund-universidad-peruana-cayetano-he-0e6116bcf2d42692Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single-Source Grant To Fund Universidad Peruana Cayetano Herediahttps://www.pharmaradar360.com/article/notice-of-award-of-a-sole-source-cooperative-agreement-to-fund-ministry-of-healt-eb8f7021caeb35f0Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Sole Source Cooperative Agreement To Fund Ministry of Health, Bhutan; National Influenza Center, Mongolia; Research Institute for Tropical Medicine, Philippines; Bangkok Metropolitan Administration, Thailandhttps://www.pharmaradar360.com/article/notice-of-award-of-a-sole-source-cooperative-agreement-to-fund-administracion-na-1a74bdaa489cfe89Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Sole Source Cooperative Agreement To Fund Administracion Nacional de Laboratorios e Institutos de Salud Dr. Carlos G. Malbran, Argentina; Instituto de Salud Publica de Chile, Chile; Ministerio de Salud Pública de Ecuador, Ecuador; Fondacioni Instituto Conmemorativo Gorgas de Esthttps://www.pharmaradar360.com/article/notice-of-award-of-a-sole-source-cooperative-agreement-to-fund-association-heada-1aa935c39263c7a7Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Sole Source Cooperative Agreement To Fund Association HEADA Cameroon; Instituto Nacional de Saude, Mozambique; Nigeria Centre for Disease Control and Prevention; National Institute of Health, Pakistan; Kinshasa School of Public Health, Democratic Republic of the Congohttps://www.pharmaradar360.com/article/notice-of-award-of-a-single-source-cooperative-agreement-to-fund-association-ins-b5035079b0e4e3d7Pharma Surgeen2026-08-05T00:00:00.000ZNotice of Award of a Single Source Cooperative Agreement To Fund Association Institut National Hygiene Publique, Cote d'Ivoire; Ministry of Health-Centers for Disease Control and Prevention, Egypt; Ethiopian Public Health Institute; Noguchi Memorial Institute for Medical Research, Ghana; Institut Nahttps://www.pharmaradar360.com/article/establishment-of-a-quantitative-medicine-innovation-network-scope-feasibility-an-d4f6976e9a1053a6Pharma Surgeen2026-08-05T00:00:00.000ZEstablishment of a Quantitative Medicine Innovation Network: Scope, Feasibility, and Opportunities; Request for Informationhttps://www.pharmaradar360.com/article/privacy-act-of-1974-matching-program-e54b3cd6ee3f2ffaPharma Surgeen2026-08-05T00:00:00.000ZPrivacy Act of 1974; Matching Programhttps://www.pharmaradar360.com/article/proposed-information-collection-activity-formative-data-collections-for-acf-rese-d21c6acfafb6c792Pharma Surgeen2026-08-05T00:00:00.000ZProposed Information Collection Activity; Formative Data Collections for ACF Research and Evaluationhttps://www.pharmaradar360.com/article/proposed-information-collection-activity-office-of-refugee-resettlement-orr-unac-38632ea1db624f5cPharma Surgeen2026-08-05T00:00:00.000ZProposed Information Collection Activity; Office of Refugee Resettlement (ORR) Unaccompanied Alien Child Health Formshttps://www.pharmaradar360.com/article/agency-information-collection-activities-submission-for-office-of-management-and-351b90fdad338a8dPharma Surgeen2026-08-05T00:00:00.000ZAgency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Food and Drug Administration Advisory Committeeshttps://www.pharmaradar360.com/article/proposed-information-collection-activity-unaccompanied-refugee-minors-program-or-de35170272622893Pharma Surgeen2026-08-05T00:00:00.000ZProposed Information Collection Activity; Unaccompanied Refugee Minors Program ORR-3 Report and ORR-4 Reporthttps://www.pharmaradar360.com/article/proposed-information-collection-activity-monitoring-and-compliance-for-office-of-51a4bf114e574ef3Pharma Surgeen2026-08-05T00:00:00.000ZProposed Information Collection Activity; Monitoring and Compliance for Office of Refugee Resettlement Care Provider Facilitieshttps://www.pharmaradar360.com/article/cleveland-clinic-pledges-1-million-to-support-teaching-kitchen-at-west-side-mark-bbfa86f80cef46c4Pharma Surgeen2026-08-05T00:00:00.000ZCleveland Clinic Pledges $1 Million to Support Teaching Kitchen at West Side Markethttps://www.pharmaradar360.com/article/united-therapeutics-corporation-reports-second-quarter-2026-financial-results-5c1249787d69b09aPharma Surgeen2026-08-05T00:00:00.000ZUnited Therapeutics Corporation Reports Second Quarter 2026 Financial Resultshttps://www.pharmaradar360.com/article/clinical-outcomes-of-uniportal-interlaminar-endoscopic-posterior-cervical-decomp-fe7168dfa275e124Pharma Surgeen2026-08-05T00:00:00.000ZCLINICAL OUTCOMES OF UNIPORTAL INTERLAMINAR ENDOSCOPIC POSTERIOR CERVICAL DECOMPRESSION FOR CERVICAL SPINAL CANAL STENOSIS: A RETROSPECTIVE STUDY OF 45 PATIENTS WITH 12-MONTH FOLLOW-UPhttps://www.pharmaradar360.com/article/is-upper-airway-obstruction-associated-with-primary-enuresis-in-children-a-clini-4d7dfe431fe02755Pharma Surgeen2026-08-05T00:00:00.000ZIs Upper Airway Obstruction Associated With Primary Enuresis in Children? A Clinical Studyhttps://www.pharmaradar360.com/article/predicting-reinfarction-after-myocardial-infarction-using-a-random-forest-model-486408ee69b70cafPharma Surgeen2026-08-05T00:00:00.000ZPredicting Reinfarction after Myocardial Infarction using a Random Forest Model: A Machine Learning Approach on an Open-Source Clinical Datasethttps://www.pharmaradar360.com/article/entrectinib-related-myocarditis-causing-a-triangular-qrs-st-t-waveform-electroca-bbd7ece26211407bPharma Surgeen2026-08-05T00:00:00.000ZEntrectinib-related Myocarditis Causing a Triangular QRS-ST-T Waveform Electrocardiographic Pattern: A Case Reporthttps://www.pharmaradar360.com/article/association-between-salt-intake-and-glycated-hemoglobin-in-subjects-with-type-2-6ac26f1a31193433Pharma Surgeen2026-08-05T00:00:00.000ZAssociation Between Salt Intake and Glycated Hemoglobin in Subjects with Type 2 Diabetes Mellitushttps://www.pharmaradar360.com/article/kidney-transplantation-in-systemic-lupus-erythematosus-and-antineutrophil-cytopl-eeaae08f600deebdPharma Surgeen2026-08-05T00:00:00.000ZKidney transplantation in systemic lupus erythematosus and antineutrophil cytoplasmic antibody-associated vasculitis: Challenges and clinical perspectiveshttps://www.pharmaradar360.com/article/from-trial-to-commercial-value-a-customer-value-architecture-for-ai-enabled-reta-548d5e2238c0e543Pharma Surgeen2026-08-05T00:00:00.000ZFrom Trial to Commercial Value: A Customer-Value Architecture for AI-Enabled Retail and Service Technologieshttps://www.pharmaradar360.com/article/antibacterial-potential-of-bacillus-sp-tbs-isolated-from-tomato-rhizosphere-85673086a411753bPharma Surgeen2026-08-05T00:00:00.000ZAntibacterial Potential Of Bacillus Sp. TBS Isolated From Tomato Rhizospherehttps://www.pharmaradar360.com/article/the-analgesic-illusion-prophylactic-self-medication-in-endurance-sport-as-a-judg-9f14a7112a08f542Pharma Surgeen2026-08-05T00:00:00.000ZThe Analgesic Illusion: Prophylactic Self-Medication in Endurance Sport as a Judgment and Decision-Making Failure Under Competitive Pressurehttps://www.pharmaradar360.com/article/sud-muhokamasi-sifatini-oshirish-orqali-sud-hukmining-barqarorligi-va-sifatini-t-84d281314b5d6c58Pharma Surgeen2026-08-05T00:00:00.000ZSUD MUHOKAMASI SIFATINI OSHIRISH ORQALI SUD HUKMINING BARQARORLIGI VA SIFATINI TAʼMINLASHNING ASOSIY YOʻNALISHLARIhttps://www.pharmaradar360.com/article/burden-and-correlates-of-sleep-disorders-among-older-adults-in-india-a-secondary-38a2217d0b1eb4e3Pharma Surgeen2026-08-05T00:00:00.000ZBurden and Correlates of Sleep Disorders Among Older Adults in India: A Secondary Analysis of the Longitudinal Ageing Study in India (LASI) Wave 1https://www.pharmaradar360.com/article/factors-associated-with-early-hematoma-expansion-in-intracerebral-hemorrhage-and-bb64e5077b44033ePharma Surgeen2026-08-05T00:00:00.000ZFactors associated with early hematoma expansion in intracerebral hemorrhage and the value of non-contrast computed tomography imaging features combined with clinical data for early identificationhttps://www.pharmaradar360.com/article/clinical-features-treatment-outcomes-and-cytokine-levels-in-pediatric-tularemia-464699243b7b9f2bPharma Surgeen2026-08-05T00:00:00.000ZClinical Features, Treatment Outcomes, and Cytokine Levels in Pediatric Tularemia Patients in Türkiyehttps://www.pharmaradar360.com/article/burden-epidemiology-and-clinical-characteristics-of-leptospirosis-within-the-uni-5249f011b3192083Pharma Surgeen2026-08-05T00:00:00.000ZBurden, Epidemiology, and Clinical Characteristics of Leptospirosis within the United States Military Health Systemhttps://www.pharmaradar360.com/article/a-non-pharmacological-intraoperative-intervention-to-reduce-pain-and-enhance-rec-c9ddb49839ca77fbPharma Surgeen2026-08-05T00:00:00.000ZA non-pharmacological intraoperative intervention to reduce pain and enhance recovery following laparoscopic cholecystectomy: a randomised controlled trialhttps://www.pharmaradar360.com/article/liquid-biopsy-in-breast-cancer-current-biomarker-platforms-and-clinical-applicat-4482222681380da8Pharma Surgeen2026-08-05T00:00:00.000ZLiquid biopsy in breast cancer: current biomarker platforms and clinical applicationshttps://www.pharmaradar360.com/article/integrating-precision-nutrition-with-glp-1-receptor-agonist-therapy-mechanisms-c-e42cd66613491273Pharma Surgeen2026-08-05T00:00:00.000ZIntegrating Precision Nutrition with GLP-1 Receptor Agonist Therapy: Mechanisms, Clinical Outcomes, and Pharmacoeconomic Implicationshttps://www.pharmaradar360.com/article/understanding-basic-concepts-of-viral-quasispecies-from-evolutionary-dynamics-to-7087cd5d64a59b25Pharma Surgeen2026-08-05T00:00:00.000ZUnderstanding Basic Concepts of Viral Quasispecies: From Evolutionary Dynamics to Clinical Relevancehttps://www.pharmaradar360.com/article/decoding-the-complexity-of-hepatocellular-carcinoma-clinical-challenges-and-targ-3fc000b2802d6e06Pharma Surgeen2026-08-05T00:00:00.000ZDecoding the Complexity of Hepatocellular Carcinoma: Clinical Challenges and Targeting HuR as a Novel Therapeutic Strategyhttps://www.pharmaradar360.com/article/pyogenic-granuloma-of-the-buccal-mucosa-mimicking-an-atypical-vascular-tumor-a-c-6e78a5259dc53aacPharma Surgeen2026-08-05T00:00:00.000ZPyogenic Granuloma of the Buccal Mucosa Mimicking an Atypical Vascular Tumor: A Case Reporthttps://www.pharmaradar360.com/article/explainable-machine-learning-for-detecting-pancreatic-cancer-from-structured-end-6aadbde9bce9da62Pharma Surgeen2026-08-05T00:00:00.000ZExplainable Machine Learning for Detecting Pancreatic Cancer from Structured Endoscopic Ultrasound Data: A Retrospective Multicenter Observational Studyhttps://www.pharmaradar360.com/article/association-between-pain-agitation-and-intracranial-pressure-with-cerebral-near-8c6dee2acc870882Pharma Surgeen2026-08-05T00:00:00.000ZAssociation Between Pain, Agitation, and Intracranial Pressure with Cerebral Near-Infrared Spectroscopy in Critically Ill Children: A Prospective Pilot Studyhttps://www.pharmaradar360.com/article/delayed-serum-creatine-kinase-elevation-after-snakebite-serial-changes-and-clini-cda7cf9752630c5bPharma Surgeen2026-08-05T00:00:00.000ZDelayed Serum Creatine Kinase Elevation After Snakebite: Serial Changes and Clinical Correlates of Myotoxicity in a Korean Tertiary-Care Cohorthttps://www.pharmaradar360.com/article/postoperative-complications-following-total-knee-arthroplasty-in-patients-with-c-50c51f0c75da044aPharma Surgeen2026-08-05T00:00:00.000ZPostoperative Complications Following Total Knee Arthroplasty in Patients with Chronic Lymphocytic Leukemiahttps://www.pharmaradar360.com/article/progressive-gingival-digital-workflow-with-chairside-abutment-customization-for-e2f65cffa000c934Pharma Surgeen2026-08-05T00:00:00.000ZProgressive Gingival Digital Workflow with Chairside Abutment Customization for Cement-Retained Implant Restorations: A Pilot Comparative Clinical Study of Two Treatment Conceptshttps://www.pharmaradar360.com/article/profile-of-people-living-with-hiv-switching-prior-antiretroviral-treatment-to-a-84dad3dc7186fc8ePharma Surgeen2026-08-05T00:00:00.000ZProfile of People Living with HIV Switching Prior Antiretroviral Treatment to a Doravirine-Based Regimen in the Real-World Clinical Setting in Greece: The Retrospective DORAVITO Studyhttps://www.pharmaradar360.com/article/improved-cognitive-flexibility-after-high-intensity-interval-training-hiit-in-in-4128f987f49b2680Pharma Surgeen2026-08-05T00:00:00.000ZImproved cognitive flexibility after high-intensity interval training (HIIT) in individuals with Parkinson's disease: a pilot randomized controlled trialhttps://www.pharmaradar360.com/article/norovirus-infection-in-pediatric-acute-gastroenteritis-epidemiology-and-clinical-d7c1beaea4dd4e33Pharma Surgeen2026-08-05T00:00:00.000ZNorovirus infection in pediatric acute gastroenteritis: epidemiology and clinical features in Ezhou, China, 2023–2025https://www.pharmaradar360.com/article/artificial-intelligence-and-machine-learning-for-precision-prevention-of-cogniti-1c89f181dd74e411Pharma Surgeen2026-08-05T00:00:00.000ZArtificial intelligence and machine learning for precision prevention of cognitive decline: integrating multimodal biomarkers, lifestyle interventions, and natural medicines from prediction to clinical practicehttps://www.pharmaradar360.com/article/impact-of-exercise-on-cognitive-efficiency-in-older-adults-with-subjective-memor-0c034940a4d13369Pharma Surgeen2026-08-05T00:00:00.000ZImpact of exercise on cognitive efficiency in older adults with subjective memory complaints: a randomized clinical trialhttps://www.pharmaradar360.com/article/a-novel-bacteriophage-capable-of-efficiently-lysing-multi-drug-resistant-klebsie-da57749943a3a5a9Pharma Surgeen2026-08-05T00:00:00.000ZA novel bacteriophage capable of efficiently lysing multi-drug-resistant Klebsiella pneumoniaehttps://www.pharmaradar360.com/article/a-tngs-based-comparative-study-on-clinical-features-and-co-detection-profiles-of-19cc8df8e4ce21bbPharma Surgeen2026-08-05T00:00:00.000ZA tNGS-based comparative study on clinical features and co-detection profiles of hospitalized children with influenza A and B viruseshttps://www.pharmaradar360.com/article/the-optimal-temperature-of-air-heated-blankets-for-preventing-intraoperative-hyp-d991d55c5ea141b5Pharma Surgeen2026-08-05T00:00:00.000ZThe optimal temperature of air-heated blankets for preventing intraoperative hypothermia in patients with gynecological tumor: a randomized controlled trialhttps://www.pharmaradar360.com/article/initial-sedation-strategy-and-clinical-outcomes-in-mechanically-ventilated-neuro-4404ef6827cf224aPharma Surgeen2026-08-05T00:00:00.000ZInitial sedation strategy and clinical outcomes in mechanically ventilated neurocritical care patients with acute brain injury: a retrospective cohort studyhttps://www.pharmaradar360.com/article/idiopathic-granulomatous-mastitis-with-gmena-syndrome-clinical-features-glucocor-e18ac4782bdad547Pharma Surgeen2026-08-05T00:00:00.000ZIdiopathic granulomatous mastitis with GMENA syndrome: clinical features, glucocorticoid response, and prognosis – a 12-year retrospective cohort study from a single centerhttps://www.pharmaradar360.com/article/prolonged-sars-cov-2-infection-in-hematologic-malignancies-clinical-impact-risk-878a37db85e4f015Pharma Surgeen2026-08-05T00:00:00.000ZProlonged SARS-CoV-2 infection in hematologic malignancies: clinical impact, risk factors and intra-host viral evolutionhttps://www.pharmaradar360.com/article/the-influence-of-integrating-national-dance-elements-into-children-dance-curricu-74af1eddd89db462Pharma Surgeen2026-08-05T00:00:00.000ZThe influence of integrating national dance elements into children dance curriculum on cultural identity and aesthetic literacy: a randomized controlled trialhttps://www.pharmaradar360.com/article/clinical-evaluation-of-early-implant-stability-using-resonance-frequency-analysi-44bd531019d79a80Pharma Surgeen2026-08-05T00:00:00.000ZClinical evaluation of early implant stability using resonance frequency analysis: a multicenter observational studyhttps://www.pharmaradar360.com/article/clinical-factors-associated-with-arrhythmia-in-obstructive-sleep-apnea-hypopnea-b6f50f5e2ee72aa0Pharma Surgeen2026-08-05T00:00:00.000ZClinical factors associated with arrhythmia in obstructive sleep apnea-hypopnea syndrome: a retrospective cross-sectional studyhttps://www.pharmaradar360.com/article/metabolic-and-clinical-markers-of-t2d-in-obese-indians-an-age-sex-matched-case-c-9dfe707a4b42e4faPharma Surgeen2026-08-05T00:00:00.000ZMetabolic and clinical markers of T2D in obese Indians: an age-sex matched case-control studyhttps://www.pharmaradar360.com/article/viral-load-rather-than-transaminase-an-international-perspective-on-the-kasl-eal-69f5f5922c18e0bdPharma Surgeen2026-08-05T00:00:00.000ZViral load rather than transaminase: an international perspective on the KASL–EALA 2026 guideline for chronic hepatitis Bhttps://www.pharmaradar360.com/article/strong-yet-flexible-multifunctional-electromechanical-responses-in-a-flexible-cr-caa5b3fceba00fc9Pharma Surgeen2026-08-05T00:00:00.000ZStrong yet Flexible: Multifunctional Electromechanical Responses in a Flexible Crystal Formed by a Zwitterionic Drug Polymorphhttps://www.pharmaradar360.com/article/dermatite-por-malassezia-spp-em-cao-com-citologia-negativa-importancia-da-correl-973cd93b200f130aPharma Surgeen2026-08-05T00:00:00.000ZDermatite por Malassezia SPP. Em cão com citologia negativa: importância da correlação clínico-terapêutica – Relato de casohttps://www.pharmaradar360.com/article/premium-pricing-after-regulatory-crisis-is-commercial-value-equivalent-to-clinic-5667edf3bd0c836cPharma Surgeen2026-08-05T00:00:00.000ZPremium Pricing After Regulatory Crisis: Is Commercial Value Equivalent to Clinical Value in the Breast Implant Market? (Preprint)https://www.pharmaradar360.com/article/the-impact-of-psychosocial-factors-on-pain-and-functional-outcomes-after-rotator-f01da58e62f46a0cPharma Surgeen2026-08-05T00:00:00.000ZThe Impact of Psychosocial Factors on Pain and Functional Outcomes After Rotator Cuff Repair: A Systematic Reviewhttps://www.pharmaradar360.com/article/retrospective-descriptive-study-of-atypical-amp-extrapelvic-manifestations-of-en-8d91e885a4118e49Pharma Surgeen2026-08-05T00:00:00.000ZRetrospective Descriptive Study of Atypical &amp; Extrapelvic manifestations of Endometriosis: Clinical Perspectiveshttps://www.pharmaradar360.com/article/retrieval-augmented-generation-for-reducing-hallucinations-in-drug-related-quest-81d8d775171d6f33Pharma Surgeen2026-08-05T00:00:00.000ZRetrieval-Augmented Generation for Reducing Hallucinations in Drug-Related Question Answering Systemshttps://www.pharmaradar360.com/article/regulations-on-drug-classification-in-indonesia-following-law-number-17-of-2023-4d27975eeea8e578Pharma Surgeen2026-08-05T00:00:00.000ZRegulations on Drug Classification in Indonesia Following Law Number 17 of 2023 concerning Healthhttps://www.pharmaradar360.com/article/engineered-extracellular-vesicles-for-cartilage-regeneration-bridging-biological-142d29151cd33e6dPharma Surgeen2026-08-05T00:00:00.000ZEngineered Extracellular Vesicles for Cartilage Regeneration: Bridging Biological Complexity to Clinical Precisionhttps://www.pharmaradar360.com/article/reproducibility-of-occlusal-contacts-in-cad-cam-splint-fabrication-analysis-usin-60d5e99bb77ef977Pharma Surgeen2026-08-05T00:00:00.000ZReproducibility of Occlusal Contacts in CAD/CAM Splint Fabrication: Analysis Using Hausdorff Distance and Clinical Validation: A Cross‑Sectional Studyhttps://www.pharmaradar360.com/article/incisional-hernia-repair-in-cirrhotic-patients-with-ascites-a-multicenter-retros-7b0fad865e7ae2f5Pharma Surgeen2026-08-05T00:00:00.000ZIncisional hernia repair in cirrhotic patients with ascites: a multicenter retrospective experiencehttps://www.pharmaradar360.com/article/revisiting-chronic-musculoskeletal-pain-as-a-biopsychosocial-disorder-6153e9f1b1835a39Pharma Surgeen2026-08-05T00:00:00.000ZRevisiting chronic musculoskeletal pain as a biopsychosocial disorderhttps://www.pharmaradar360.com/article/combine-advanced-deep-neural-networks-with-the-smote-technique-for-the-classific-2b97086b45b0ebadPharma Surgeen2026-08-05T00:00:00.000ZCombine Advanced Deep Neural Networks with the SMOTE technique for the Classification of Eczema in Clinical Imageshttps://www.pharmaradar360.com/article/feasibility-and-outcomes-of-crossflow-membrane-plasmapheresis-for-long-covid-in-aaf5d9cb73bcdaccPharma Surgeen2026-08-05T00:00:00.000ZFeasibility and outcomes of crossflow membrane plasmapheresis for long COVID in Suriname: a randomized double-blind placebo-controlled pilot trialhttps://www.pharmaradar360.com/article/maternal-clinical-pathology-49f6410d6b583e42Pharma Surgeen2026-08-05T00:00:00.000ZMaternal Clinical Pathologyhttps://www.pharmaradar360.com/article/intensify-a-randomized-controlled-trial-to-investigate-the-effect-of-an-early-in-b5c7ed92129a49efPharma Surgeen2026-08-05T00:00:00.000ZINTENSIFY—a randomized, controlled trial to investigate the effect of an early intensified pharmacological treatment for major psychiatric disorders after treatment failure in the current episode: a study protocolhttps://www.pharmaradar360.com/article/effectiveness-of-the-active-school-quasi-experimental-cluster-controlled-trial-i-5429c0361ffc5a14Pharma Surgeen2026-08-05T00:00:00.000ZEffectiveness of the Active School quasi-experimental cluster-controlled trial: Impact on objectively measured physical activity in Swiss secondary school students after 12 monthshttps://www.pharmaradar360.com/article/decider-2-prospective-randomized-multicenter-phase-iii-trial-of-decitabine-and-v-465c47d43475e809Pharma Surgeen2026-08-05T00:00:00.000ZDECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapyhttps://www.pharmaradar360.com/article/core-competencies-of-clinical-nurses-in-disaster-management-a-scoping-review-b69b97e47a259d4dPharma Surgeen2026-08-05T00:00:00.000ZCore competencies of clinical nurses in disaster management: a scoping reviewhttps://www.pharmaradar360.com/article/developmental-relations-between-oppositional-defiant-disorder-and-depression-in-1cea6c522a2c81ebPharma Surgeen2026-08-05T00:00:00.000ZDevelopmental Relations Between Oppositional Defiant Disorder and Depression in Childhood: A Symptom Level Perspectivehttps://www.pharmaradar360.com/article/recombination-between-two-adjacent-ice-i-san-i-95-generated-a-new-transferable-i-f52c2fb2b72e4182Pharma Surgeen2026-08-05T00:00:00.000ZRecombination Between Two Adjacent ICE <i>San</i> 95 Generated a New Transferable Integrative and Conjugative Element in <i>Streptococcus agalactiae</i>https://www.pharmaradar360.com/article/translating-evidence-on-pulse-oximetry-bias-into-equitable-nursing-practice-comm-43f45eeefaeb81b9Pharma Surgeen2026-08-05T00:00:00.000ZTranslating Evidence on Pulse Oximetry Bias Into Equitable Nursing Practice: Commentary on Cotton et al. (2025)https://www.pharmaradar360.com/article/sustained-high-prevalence-of-multiple-antimalarial-drug-resistance-markers-in-ug-945f8889fd77cc6cPharma Surgeen2026-08-05T00:00:00.000ZSustained high prevalence of multiple antimalarial drug resistance markers in Uganda in 2023–2024https://www.pharmaradar360.com/article/comparison-of-plasma-protein-fractions-and-electrophoretograms-in-non-laying-and-05a2c633ab69e4c8Pharma Surgeen2026-08-05T00:00:00.000ZComparison of Plasma Protein Fractions and Electrophoretograms in Non‐Laying and Egg‐Laying Domestic Chickenshttps://www.pharmaradar360.com/article/silent-surveillance-neonatal-nurses-recognition-interpretation-and-escalation-of-c5b6843e3bfaaed9Pharma Surgeen2026-08-05T00:00:00.000ZSilent Surveillance: Neonatal Nurses' Recognition, Interpretation and Escalation of Early Clinical Deterioration—An Interpretive Description Studyhttps://www.pharmaradar360.com/article/processionary-moth-exposure-in-europe-toxic-irritant-and-immunoglobulin-e-mediat-08fc597bfb75b37aPharma Surgeen2026-08-05T00:00:00.000ZProcessionary Moth Exposure in Europe: Toxic–Irritant and Immunoglobulin E‐Mediated Endotypes, Diagnosis and Managementhttps://www.pharmaradar360.com/article/clinical-benefits-and-risks-of-the-wall-push-technique-in-endovascular-repair-of-fe943a01f2fa2cffPharma Surgeen2026-08-05T00:00:00.000ZClinical Benefits and Risks of the Wall-Push Technique in Endovascular Repair of Abdominal Aortic Aneurysm with Severely Angulated Neck: A Case Reporthttps://www.pharmaradar360.com/article/enriching-microbial-cell-free-dna-in-clinical-metagenomics-using-epigenetic-filt-534c430ff0d4e7ffPharma Surgeen2026-08-05T00:00:00.000ZEnriching Microbial Cell-Free DNA in Clinical Metagenomics Using Epigenetic Filtershttps://www.pharmaradar360.com/article/formulation-and-evaluation-of-etoposide-loaded-dextran-polymeric-nanoparticles-f-202096dc4e0f35cePharma Surgeen2026-08-05T00:00:00.000ZFormulation and evaluation of etoposide-loaded dextran polymeric nanoparticles fabricated with hyaluronic acid for the treatment of colorectal cancer using network pharmacology, <i>in-silico</i> , <i>in-vitro</i> , and <i>in-vivo</i> approacheshttps://www.pharmaradar360.com/article/environmental-and-physiological-determinants-of-somatic-cell-count-and-clinical-1528b388335a870aPharma Surgeen2026-08-05T00:00:00.000ZEnvironmental and physiological determinants of somatic cell count and clinical mastitis in primiparous Holstein cowshttps://www.pharmaradar360.com/article/safety-tolerability-and-pharmacokinetics-of-oral-fm888-in-healthy-chinese-adults-1a1397c97e47f736Pharma Surgeen2026-08-05T00:00:00.000ZSafety, tolerability, and pharmacokinetics of oral FM888 in healthy Chinese adults: a Phase I, randomized, double-blind, placebo-controlled studyhttps://www.pharmaradar360.com/article/curcumin-protects-sh-sy5y-cells-against-glutamate-induced-excitotoxicity-by-main-225fb2b5c13e4784Pharma Surgeen2026-08-05T00:00:00.000ZCurcumin protects SH-SY5Y cells against glutamate-induced excitotoxicity by maintaining genomic integrity and antioxidant balancehttps://www.pharmaradar360.com/article/dose-controlled-script-training-for-aphasia-a-quasi-randomized-pilot-clinical-tr-1d5ae793994cac7cPharma Surgeen2026-08-05T00:00:00.000ZDose-Controlled Script Training for Aphasia: A Quasi-Randomized Pilot Clinical Trial Examining Treatment Frequencyhttps://www.pharmaradar360.com/article/development-and-evaluation-of-a-hybrid-clinical-and-deep-learning-ecg-model-for-fedb175d566d6dbfPharma Surgeen2026-08-05T00:00:00.000ZDevelopment and evaluation of a hybrid clinical and deep-learning ECG model for predicting in-hospital cardiac arresthttps://www.pharmaradar360.com/article/dronabinol-for-nightmares-in-post-traumatic-stress-disorder-a-randomized-control-afe5a4cfaceed3f9Pharma Surgeen2026-08-05T00:00:00.000ZDronabinol for nightmares in post-traumatic stress disorder: a randomized controlled trialhttps://www.pharmaradar360.com/article/combining-orally-available-selective-estrogen-receptor-degraders-with-pan-her-ty-ec845a2be82d3129Pharma Surgeen2026-08-05T00:00:00.000ZCombining orally available selective estrogen receptor degraders with pan-HER tyrosine kinase inhibitor neratinib in pre-clinical models of HER2+/ER+ breast cancerhttps://www.pharmaradar360.com/article/plant-based-dietary-patterns-and-risk-of-breast-cancer-a-systematic-review-and-m-a50321670cc7ffdfPharma Surgeen2026-08-05T00:00:00.000ZPlant-based dietary patterns and risk of breast cancer: A systematic review and meta-analysishttps://www.pharmaradar360.com/article/the-role-of-genetic-variation-in-apolipoprotein-response-to-diet-among-brazilian-bbf055c4a419fc75Pharma Surgeen2026-08-05T00:00:00.000ZThe role of genetic variation in apolipoprotein response to diet among Brazilians with cardiovascular diseasehttps://www.pharmaradar360.com/article/clinical-and-genomic-determinants-of-extraordinary-response-and-resistance-to-an-2d8adef2ebfbf32cPharma Surgeen2026-08-05T00:00:00.000ZClinical and genomic determinants of extraordinary response and resistance to androgen receptor pathway inhibitors in men with metastatic androgen pathway modulator sensitive (APMS) prostate cancerhttps://www.pharmaradar360.com/article/vasopressin-for-hemodynamic-support-in-neonates-current-evidence-and-clinical-ap-10fd2a6ead622f32Pharma Surgeen2026-08-05T00:00:00.000ZVasopressin for hemodynamic support in neonates: current evidence and clinical applicationshttps://www.pharmaradar360.com/article/magneto-fluorescent-mn-doped-cd-zif-8-kappa-carrageenan-biohydrogel-a-dual-model-1088d9dfd0e948e7Pharma Surgeen2026-08-05T00:00:00.000ZMagneto-Fluorescent Mn-Doped CD@ZIF-8@Kappa Carrageenan Biohydrogel—A Dual Model Therapeutic and Diagnostic Agent for Targeted Drug Delivery and Cancer Therapyhttps://www.pharmaradar360.com/article/jun-chen-zuo-shi-the-chinese-medical-perspective-on-clinical-oncology-nutritiona-969c1ef88a85c46ePharma Surgeen2026-08-05T00:00:00.000Z“Jun-Chen-Zuo-Shi” - the Chinese medical perspective on clinical oncology nutritional therapyhttps://www.pharmaradar360.com/article/correction-a-pilot-randomized-trial-effectiveness-of-a-five-day-online-audio-vis-a78e7d352fbdd1fePharma Surgeen2026-08-05T00:00:00.000ZCorrection: A Pilot Randomized Trial: Effectiveness of a Five-day Online Audio-Visual Contagious Laughter Intervention to Enhance Well-being in Adultshttps://www.pharmaradar360.com/article/diagnostic-utility-of-body-fat-distribution-parameters-in-distinguishing-osteosa-05f7a4a8c0f93c3bPharma Surgeen2026-08-05T00:00:00.000ZDiagnostic utility of body fat distribution parameters in distinguishing osteosarcopenia from osteoporosis or sarcopenia alone in postmenopausal women: a retrospective cross-sectional studyhttps://www.pharmaradar360.com/article/association-between-intrinsic-capacity-transitions-and-the-risk-of-diabetes-in-m-0cd5ba1bce234fabPharma Surgeen2026-08-05T00:00:00.000ZAssociation between intrinsic capacity transitions and the risk of diabetes in middle-aged and older adultshttps://www.pharmaradar360.com/article/dexmedetomidine-versus-dexamethasone-as-an-adjuvant-in-tap-blocks-for-cesarean-s-5709b792f1557fa0Pharma Surgeen2026-08-05T00:00:00.000ZDexmedetomidine Versus Dexamethasone as an Adjuvant in TAP Blocks for Cesarean Section: A Meta-Analysis of Randomized Clinical Trialshttps://www.pharmaradar360.com/article/platelets-as-regulators-of-cancer-immunity-mechanisms-and-therapeutic-perspectiv-61cc186bcb2a738dPharma Surgeen2026-08-05T00:00:00.000ZPlatelets as regulators of cancer immunity: mechanisms and therapeutic perspectiveshttps://www.pharmaradar360.com/article/correction-a-prospective-experimental-randomized-controlled-trial-to-investigate-5545579d6364d653Pharma Surgeen2026-08-05T00:00:00.000ZCorrection: A prospective experimental randomized controlled trial to investigate the effect of virtual reality (VR) technology on improving clinical pregnancy rates and lowering anxiety for IVF patients undergoing frozen embryo transfer (FET)https://www.pharmaradar360.com/article/lytic-activity-of-f8-like-phage-spm-1-against-one-health-lineages-of-carbapenem-822a6692c4620ddfPharma Surgeen2026-08-05T00:00:00.000ZLytic activity of F8-like phage φSPM-1 against One Health lineages of carbapenem-resistant Pseudomonas aeruginosahttps://www.pharmaradar360.com/article/a-clinical-triage-score-for-mlpa-testing-in-children-with-microcytosis-suspected-557806254439e9f4Pharma Surgeen2026-08-05T00:00:00.000ZA clinical triage score for MLPA testing in children with microcytosis suspected of deletional alpha-thalassemiahttps://www.pharmaradar360.com/article/drug-resistance-assessment-of-commonly-used-anthelmintics-and-their-combination-18f9ac03c02839b9Pharma Surgeen2026-08-05T00:00:00.000ZDrug Resistance Assessment of Commonly Used Anthelmintics, and Their Combination Effect in Naturally Infected Sheep: The Case of Kaffa Zone, Southwestern Ethiopiahttps://www.pharmaradar360.com/article/one-year-transcutaneous-tibial-nerve-stimulation-treatment-persistence-in-lower-c9c79b6dfd835427Pharma Surgeen2026-08-05T00:00:00.000ZOne‐Year Transcutaneous Tibial Nerve Stimulation Treatment Persistence in Lower Urinary Tract Dysfunction: Clinical and Urodynamic Associated Factors in a Prospective Observational Studyhttps://www.pharmaradar360.com/article/risk-factors-for-immune-related-adverse-events-tackling-temporality-and-clinical-a399c2919f6b6754Pharma Surgeen2026-08-05T00:00:00.000ZRisk Factors for Immune‐Related Adverse Events: Tackling Temporality and Clinical Heterogeneityhttps://www.pharmaradar360.com/article/nct07747896-effect-of-a-coordinated-primary-care-based-mdt-model-on-the-treatmen-b792a5d1523d87c7Pharma Surgeen2026-08-05T00:00:00.000ZNCT07747896: Effect of a Coordinated Primary-care-Based MDT-model on the Treatment of Hard-to-heal Ulcershttps://www.pharmaradar360.com/article/nct07747883-trial-of-device-that-is-not-approved-or-cleared-by-the-u-s-fda-d07c1688f7e118faPharma Surgeen2026-08-05T00:00:00.000ZNCT07747883: [Trial of device that is not approved or cleared by the U.S. FDA]https://www.pharmaradar360.com/article/nct07747779-comparison-of-hormonal-response-to-a-mixed-meal-tolerance-test-after-bb7fdd8a7d3eb307Pharma Surgeen2026-08-05T00:00:00.000ZNCT07747779: Comparison of Hormonal Response to a Mixed-Meal Tolerance Test After Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve Gastrectomy With Duodenojejunal Bypass in Patients With Super Morbid Obesity: A Prospective Single-Center Non-Inferiority Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07747766-program-for-alleviating-relationship-trauma-and-stress-for-intimate-b9779cb964d9fa19Pharma Surgeen2026-08-05T00:00:00.000ZNCT07747766: Program for Alleviating Relationship Trauma and Stress for Intimate Partner Violence - Randomized Control Trialhttps://www.pharmaradar360.com/article/nct07747753-comparison-of-post-operative-pain-and-levels-of-mmp-9-following-root-370c65bfe22ff932Pharma Surgeen2026-08-05T00:00:00.000ZNCT07747753: Comparison of Post-operative Pain and Levels of MMP -9 Following Root Canal Irrigation With Sodium Hypochlorite Versus Cold Atmospheric Plasma in Patient With Necrotic Single Rooted Teeth: Randomized Clinical Trialhttps://www.pharmaradar360.com/article/nct07747038-caudal-block-v-s-local-wound-infiltration-for-pain-control-in-pediat-85eb8dedd64bd692Pharma Surgeen2026-08-05T00:00:00.000ZNCT07747038: Caudal Block v/s Local Wound Infiltration for Pain Control in Pediatric Patients After Operation for Inguinal Herniahttps://www.pharmaradar360.com/article/nct07746401-recovery-opportunities-through-ongoing-treatment-sustainment-bbc2d0707f8039a7Pharma Surgeen2026-08-05T00:00:00.000ZNCT07746401: Recovery Opportunities Through Ongoing Treatment Sustainmenthttps://www.pharmaradar360.com/article/nct07746297-the-panhis-study-sexual-health-in-spanish-speaking-adults-a-cross-se-a217e2e41f2ecfc5Pharma Surgeen2026-08-05T00:00:00.000ZNCT07746297: The PANHIS Study: Sexual Health in Spanish-Speaking Adults - A Cross-Sectional Online Surveyhttps://www.pharmaradar360.com/article/nct07648641-a-clinical-trial-of-the-13-valent-pneumococcal-polysaccharide-conjug-cb8495ca302b9860Pharma Surgeen2026-08-05T00:00:00.000ZNCT07648641: A Clinical Trial of the 13-Valent Pneumococcal Polysaccharide Conjugate Vaccine (CRM197/Tetanus Toxoid)https://www.pharmaradar360.com/article/nct07619547-longitudinal-immunophenotyping-of-patients-with-inflammatory-bowel-d-3a796411228812d2Pharma Surgeen2026-08-05T00:00:00.000ZNCT07619547: Longitudinal Immunophenotyping of Patients With Inflammatory Bowel Diseasehttps://www.pharmaradar360.com/article/nct07619443-a-clinical-study-of-mk-7262-and-enlicitide-in-healthy-participants-m-44bcfe61bab95ff2Pharma Surgeen2026-08-05T00:00:00.000ZNCT07619443: A Clinical Study of MK-7262 and Enlicitide in Healthy Participants (MK-7262-003)https://www.pharmaradar360.com/article/nct07606378-efficacy-of-prp-injections-in-reducing-pain-for-myogenous-tmd-patien-9479b146eedf9815Pharma Surgeen2026-08-05T00:00:00.000ZNCT07606378: Efficacy of PRP Injections in Reducing Pain for Myogenous TMD Patientshttps://www.pharmaradar360.com/article/nct07574541-multitargeted-recombinant-ad5-psa-muc-1-brachyury-based-immunotherap-0f3af0b930fedd23Pharma Surgeen2026-08-05T00:00:00.000ZNCT07574541: Multitargeted Recombinant Ad5 PSA/MUC-1/Brachyury-Based Immunotherapy (TriAdeno) Vaccine With IL-15 Superagonist N-803 in Participants With Clinically Localized Prostate Cancer Undergoing Active Surveillancehttps://www.pharmaradar360.com/article/nct07523750-a-study-of-varipulse-pulsed-field-ablation-pfa-catheter-and-farawave-0045ac1380aaec49Pharma Surgeen2026-08-05T00:00:00.000ZNCT07523750: A Study of VARIPULSE Pulsed Field Ablation (PFA) Catheter and FARAWAVE PFA Catheter in the Treatment of Participants With Persistent Atrial Fibrillationhttps://www.pharmaradar360.com/article/nct07520461-microbiome-targeted-diet-therapy-in-ulcerative-colitis-8ea4d6422e566cf6Pharma Surgeen2026-08-05T00:00:00.000ZNCT07520461: Microbiome-targeted Diet Therapy in Ulcerative Colitishttps://www.pharmaradar360.com/article/nct07479576-a-comparative-phase-1-study-to-evaluate-the-pharmacokinetic-and-safe-f6ad79a9f1717bf4Pharma Surgeen2026-08-05T00:00:00.000ZNCT07479576: A Comparative Phase 1 Study to Evaluate the Pharmacokinetic and Safety of QL2106 vs Tremfye® in Healthy Subjectshttps://www.pharmaradar360.com/article/nct07437976-a-natural-history-of-genetic-and-environmental-predictors-of-puberta-6b2ccb1e0c1c166dPharma Surgeen2026-08-05T00:00:00.000ZNCT07437976: A Natural History of Genetic and Environmental Predictors of Pubertal Timing Among Youth With Obesityhttps://www.pharmaradar360.com/article/nct07388550-phase-i-open-label-safety-trial-of-pembrolizumab-for-neurological-po-c8883fe8549f9913Pharma Surgeen2026-08-05T00:00:00.000ZNCT07388550: Phase I Open-Label Safety Trial of Pembrolizumab for Neurological Post- Acute Sequelae of SARS-CoV-2 (PD1-PASC I)https://www.pharmaradar360.com/article/nct07349121-option-emea-clinical-trial-476430b004bddb0ePharma Surgeen2026-08-05T00:00:00.000ZNCT07349121: OPTION-EMEA Clinical Trialhttps://www.pharmaradar360.com/article/nct07294924-prediction-of-response-to-depression-interventions-accelerated-rtms-db621fdc359ac1c3Pharma Surgeen2026-08-05T00:00:00.000ZNCT07294924: Prediction of REsponse to Depression Interventions (Accelerated rTMS) Using Clinical and TD-fNIRS Measurementshttps://www.pharmaradar360.com/article/nct07293247-a-study-of-targeted-post-surgery-radiation-therapy-for-non-small-cel-d1c0e9bd8d22fc8aPharma Surgeen2026-08-05T00:00:00.000ZNCT07293247: A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatmenthttps://www.pharmaradar360.com/article/nct07215910-testing-addition-of-an-anti-cancer-drug-vorasidenib-to-temozolomide-44a0248e8a1c505fPharma Surgeen2026-08-05T00:00:00.000ZNCT07215910: Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancerhttps://www.pharmaradar360.com/article/nct07153146-safety-tolerability-pharmacokinetics-and-pharmacodynamics-of-pn-881-b720f39a700e513cPharma Surgeen2026-08-05T00:00:00.000ZNCT07153146: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.https://www.pharmaradar360.com/article/nct07098286-enhancing-resilience-among-patients-with-stroke-implementation-of-hi-aa57e4177a8accc7Pharma Surgeen2026-08-05T00:00:00.000ZNCT07098286: Enhancing Resilience Among Patients With Stroke: Implementation of High Intensity Home-based Rehabilitationhttps://www.pharmaradar360.com/article/nct06816108-a-study-of-ono-7428-in-participants-with-unresectable-advanced-or-re-c05815a1df19bdb9Pharma Surgeen2026-08-05T00:00:00.000ZNCT06816108: A Study of ONO-7428 in Participants With Unresectable Advanced or Recurrent Solid Tumorshttps://www.pharmaradar360.com/article/nct06800196-a-study-of-knt-0916-in-treatment-of-unresectable-or-metastatic-solid-34c3be5a46ef12ecPharma Surgeen2026-08-05T00:00:00.000ZNCT06800196: A Study of KNT-0916 in Treatment of Unresectable or Metastatic Solid Tumors With FGFR2 Alterationshttps://www.pharmaradar360.com/article/nct06790693-a-study-evaluating-the-efficacy-and-safety-of-inavolisib-plus-cdk4-6-6f1e9caf08c3d834Pharma Surgeen2026-08-05T00:00:00.000ZNCT06790693: A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancerhttps://www.pharmaradar360.com/article/nct06770660-effect-of-tele-exercise-on-cardiorespiratory-fitness-in-paediatrics-521747ffb636c0dbPharma Surgeen2026-08-05T00:00:00.000ZNCT06770660: Effect of Tele-exercise on Cardiorespiratory Fitness in Paediatricshttps://www.pharmaradar360.com/article/nct06730113-youth-onset-type-2-diabetes-and-heart-disease-the-young-at-heart-pro-d546e827d4c5aee5Pharma Surgeen2026-08-05T00:00:00.000ZNCT06730113: Youth-Onset Type 2 Diabetes and Heart Disease: The Young at Heart Prospective Cohort Studyhttps://www.pharmaradar360.com/article/nct06669247-a-study-to-assess-the-safety-and-anti-tumor-activity-of-regn7945-in-61dbdd6147951349Pharma Surgeen2026-08-05T00:00:00.000ZNCT06669247: A Study to Assess the Safety and Anti-Tumor Activity of REGN7945 in Combination With Linvoseltamab in Adult Participants With Relapsed/Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct06632977-targeted-treatment-for-metastatic-prostate-cancer-the-predict-trial-91465c1e517310b1Pharma Surgeen2026-08-05T00:00:00.000ZNCT06632977: Targeted Treatment for Metastatic Prostate Cancer, The PREDICT Trialhttps://www.pharmaradar360.com/article/nct06615973-screening-for-social-determinants-of-health-sdoh-and-cognitive-funct-69af5e89852e6a1aPharma Surgeen2026-08-05T00:00:00.000ZNCT06615973: Screening for Social Determinants of Health (SDOH) and Cognitive Function in Individuals With History of Strokehttps://www.pharmaradar360.com/article/nct06568861-a-study-to-evaluate-the-pharmacokinetics-safety-and-tolerability-of-f1d7598d6756a982Pharma Surgeen2026-08-05T00:00:00.000ZNCT06568861: A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ALG-097558 in Subjects With Hepatic Impairment and in Healthy Subjects With Normal Hepatic Functionhttps://www.pharmaradar360.com/article/nct06401928-electrical-brain-stimulation-for-treatment-of-secondary-symptoms-in-3986a36f84feb6edPharma Surgeen2026-08-05T00:00:00.000ZNCT06401928: Electrical Brain Stimulation for Treatment of Secondary Symptoms in Multiple Sclerosishttps://www.pharmaradar360.com/article/nct06379789-a-study-to-investigate-the-safety-and-effectiveness-of-a-coagulation-a1215b221df7eb81Pharma Surgeen2026-08-05T00:00:00.000ZNCT06379789: A Study to Investigate the Safety and Effectiveness of a Coagulation Factor IX Gene Insertion Therapy (REGV131-LNP1265) in Pediatric, Adolescent and Adult Participants With Hemophilia Bhttps://www.pharmaradar360.com/article/nct06274749-effects-of-urolithin-a-supplementation-on-glucose-metabolism-in-heal-597167a31fc2a3baPharma Surgeen2026-08-05T00:00:00.000ZNCT06274749: Effects of Urolithin A Supplementation on Glucose Metabolism in Healthy Adults 55 >= Years Old: A Randomized Triple-Masked Controlled Clinical Trialhttps://www.pharmaradar360.com/article/nct06238466-a-study-to-investigate-safety-tolerability-pharmacokinetics-and-phar-ac8764ca545dffe9Pharma Surgeen2026-08-05T00:00:00.000ZNCT06238466: A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemiahttps://www.pharmaradar360.com/article/nct06232044-testing-the-combination-of-two-approved-drugs-and-one-experimental-d-5e711b3b891258e4Pharma Surgeen2026-08-05T00:00:00.000ZNCT06232044: Testing the Combination of Two Approved Drugs and One Experimental Drug in Patients With Relapsed or Refractory Multiple Myelomahttps://www.pharmaradar360.com/article/nct06203210-a-study-of-ifinatamab-deruxtecan-versus-treatment-of-physician-s-cho-bfbf16cc68d772c4Pharma Surgeen2026-08-05T00:00:00.000ZNCT06203210: A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancerhttps://www.pharmaradar360.com/article/nct06108089-novel-hypoxia-imaging-for-head-and-neck-cancer-imaging-phenotype-for-61d59e583ec9264cPharma Surgeen2026-08-05T00:00:00.000ZNCT06108089: Novel Hypoxia Imaging for Head and Neck Cancer: Imaging Phenotype for Personalized Treatmenthttps://www.pharmaradar360.com/article/nct05849207-post-transplant-cyclophosphamide-in-patients-aged-65-years-undergoin-e657cf602ae363caPharma Surgeen2026-08-05T00:00:00.000ZNCT05849207: Post-Transplant Cyclophosphamide in Patients Aged >/= 65 Years Undergoing Haploidentical Transplanthttps://www.pharmaradar360.com/article/nct05708352-a-phase-2-study-of-the-ketogenic-diet-vs-standard-anti-cancer-diet-g-00c72aab94a59645Pharma Surgeen2026-08-05T00:00:00.000ZNCT05708352: A Phase 2 Study of the Ketogenic Diet vs Standard Anti-cancer Diet Guidance for Patients With Glioblastoma in Combination With Standard-of-care Treatmenthttps://www.pharmaradar360.com/article/nct05701800-a-study-to-evaluate-the-safety-reactogenicity-and-immunogenicity-of-189ca83dca27f584Pharma Surgeen2026-08-05T00:00:00.000ZNCT05701800: A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1468 in Healthy Adults ≥50 Years of Agehttps://www.pharmaradar360.com/article/nct05675410-a-study-to-compare-standard-therapy-to-treat-hodgkin-lymphoma-to-the-197bf22bc09e3437Pharma Surgeen2026-08-05T00:00:00.000ZNCT05675410: A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumabhttps://www.pharmaradar360.com/article/nct05583617-a-study-evaluating-the-safety-and-efficacy-of-multiple-treatments-in-68c84731b2883a05Pharma Surgeen2026-08-05T00:00:00.000ZNCT05583617: A Study Evaluating the Safety and Efficacy of Multiple Treatments in Participants With Multiple Myelomahttps://www.pharmaradar360.com/article/nct05091424-a-study-evaluating-the-safety-efficacy-and-pharmacokinetics-of-mosun-bd9f05421ff2d8f5Pharma Surgeen2026-08-05T00:00:00.000ZNCT05091424: A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemiahttps://www.pharmaradar360.com/article/nct04858334-apollo-a-randomized-phase-ii-double-blind-study-of-olaparib-versus-p-3c62b6e166005acfPharma Surgeen2026-08-05T00:00:00.000ZNCT04858334: APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutationhttps://www.pharmaradar360.com/article/nct04417283-project-hope-1000-health-outcomes-pregnancy-exposures-9418d19f938fa81aPharma Surgeen2026-08-05T00:00:00.000ZNCT04417283: Project HOPE 1000: Health Outcomes Pregnancy Exposureshttps://www.pharmaradar360.com/article/nct03459846-a-study-of-durvalumab-alone-and-durvalumab-olaparib-in-advanced-plat-df8297cadf3094a8Pharma Surgeen2026-08-05T00:00:00.000ZNCT03459846: A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)https://www.pharmaradar360.com/article/nct02494869-dose-response-of-aerobic-training-in-women-at-high-risk-for-developm-079c01b6c8fa85faPharma Surgeen2026-08-05T00:00:00.000ZNCT02494869: Dose-Response of Aerobic Training in Women at High-Risk for Development of Breast Cancerhttps://www.pharmaradar360.com/article/nct00911560-bivalent-vaccine-with-escalating-doses-of-the-immunological-adjuvant-e40dbd53c25032d1Pharma Surgeen2026-08-05T00:00:00.000ZNCT00911560: Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastomahttps://www.pharmaradar360.com/article/walking-the-line-navigating-aks-risk-in-pharmaceutical-speaker-programs-and-pati-50733c6fa4cdf507Pharma Surgeen2026-08-04T23:40:37.000ZWalking the Line: Navigating AKS Risk in Pharmaceutical Speaker Programs and Patient Supporthttps://www.pharmaradar360.com/article/young-chairs-hearing-on-american-biotechnology-leadership-building-a-resilient-h-71f158406af87202Pharma Surgeen2026-08-04T23:34:54.000ZYoung Chairs Hearing on American Biotechnology Leadership, Building a Resilient Health Care Futurehttps://www.pharmaradar360.com/article/biotech-founder-claims-he-was-excluded-from-gsk-deal-a33afd8600b97bb1Pharma Surgeen2026-08-04T23:27:00.000ZBiotech Founder Claims He Was Excluded From GSK Dealhttps://www.pharmaradar360.com/article/enterprise-value-to-revenue-forward-of-kintor-pharmaceutical-ltd-otc-kntpf-956c53ba51bc6e52Pharma Surgeen2026-08-04T23:20:08.000ZEnterprise value to revenue forward of KINTOR PHARMACEUTICAL LTD. – OTC:KNTPFhttps://www.pharmaradar360.com/article/fda-stance-on-cbd-gummies-2025-regulations-view-huixu0mbm-41bf651437007da8Pharma Surgeen2026-08-04T23:16:39.000ZFDA Stance on CBD Gummies 2025 Regulations - View hUixU0MbMhttps://www.pharmaradar360.com/article/is-cbd-gummies-a-drug-view-nys2esxcl-2d83b92dd9dc59c4Pharma Surgeen2026-08-04T23:13:26.000ZIs CBD Gummies a Drug? - View NyS2eSXCLhttps://www.pharmaradar360.com/article/etfs-investing-in-chugai-pharmaceutical-co-ltd-unsponsored-adr-stocks-ba3adef8f68bdd2bPharma Surgeen2026-08-04T23:08:43.000ZETFs Investing in Chugai Pharmaceutical Co., Ltd. Unsponsored ADR Stockshttps://www.pharmaradar360.com/article/fda-warnings-slimming-tea-sibutramine-why-these-products-pose-serious-health-ris-7f940d8b70939513Pharma Surgeen2026-08-04T23:05:14.000ZFDA Warnings Slimming Tea Sibutramine: Why These Products Pose Serious Health Risks and How to Stay Safe *ZFRa7D0tL*https://www.pharmaradar360.com/article/ono-pharmaceutical-co-ltd-2027-q1-results-earnings-call-presentation-otcmkts-oph-243e30b935db1f1fPharma Surgeen2026-08-04T23:04:33.000ZOno Pharmaceutical Co., Ltd. 2027 Q1 - Results - Earnings Call Presentation (OTCMKTS:OPHLY) 2026-08-04https://www.pharmaradar360.com/article/ultragenyx-pharmaceutical-inc-reports-results-for-the-quarter-ended-june-30-earn-61a26f3e18a2387aPharma Surgeen2026-08-04T23:04:23.000ZUltragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summaryhttps://www.pharmaradar360.com/article/latigo-blossomhill-detail-ipo-plans-for-pain-and-cancer-push-5bcb3045c0d04ef5Pharma Surgeen2026-08-04T23:01:04.000ZLatigo, BlossomHill detail IPO plans for pain and cancer push